Kala Pharmaceuticals, Inc. (KALA): Price and Financial Metrics

Kala Pharmaceuticals, Inc. (KALA): $0.30

-0.02 (-6.25%)

POWR Rating

Component Grades














  • Growth is the dimension where KALA ranks best; there it ranks ahead of 62.35% of US stocks.
  • KALA's strongest trending metric is Sentiment; it's been moving up over the last 179 days.
  • KALA ranks lowest in Stability; there it ranks in the 5th percentile.

KALA Stock Summary

  • As for revenue growth, note that KALA's revenue has grown 119.12% over the past 12 months; that beats the revenue growth of 93.13% of US companies in our set.
  • In terms of volatility of its share price, KALA is more volatile than 97.92% of stocks we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for KALA comes in at -64.24% -- higher than that of only 6.64% of stocks in our set.
  • Stocks that are quantitatively similar to KALA, based on their financial statements, market capitalization, and price volatility, are ECOR, ACRX, XXII, ZKIN, and SIBN.
  • KALA's SEC filings can be seen here. And to visit Kala Pharmaceuticals Inc's official web site, go to www.kalarx.com.

KALA Valuation Summary

  • In comparison to the median Healthcare stock, KALA's EV/EBIT ratio is 105.46% lower, now standing at -1.6.
  • KALA's EV/EBIT ratio has moved up 9.3 over the prior 50 months.
  • Over the past 50 months, KALA's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for KALA.

Stock Date P/S P/B P/E EV/EBIT
KALA 2021-08-31 20.4 2.6 -1.7 -1.6
KALA 2021-08-30 20.1 2.6 -1.7 -1.5
KALA 2021-08-27 19.6 2.5 -1.7 -1.5
KALA 2021-08-26 18.3 2.3 -1.6 -1.4
KALA 2021-08-25 18.5 2.4 -1.6 -1.4
KALA 2021-08-24 18.2 2.3 -1.6 -1.4

KALA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • KALA has a Quality Grade of C, ranking ahead of 25.42% of graded US stocks.
  • KALA's asset turnover comes in at 0.048 -- ranking 323rd of 680 Pharmaceutical Products stocks.
  • AERI, NBY, and FLXN are the stocks whose asset turnover ratios are most correlated with KALA.

The table below shows KALA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.048 0.644 -0.573
2021-03-31 0.037 0.582 -0.486
2020-12-31 0.027 0.501 -0.475
2020-09-30 0.024 0.517 -0.484
2020-06-30 0.022 0.443 -0.584
2020-03-31 0.031 0.632 -0.695

KALA Price Target

For more insight on analysts targets of KALA, see our KALA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.79 Average Broker Recommendation 1.5 (Moderate Buy)

KALA Stock Price Chart Interactive Chart >

Price chart for KALA

KALA Price/Volume Stats

Current price $0.30 52-week high $5.47
Prev. close $0.32 52-week low $0.30
Day low $0.30 Volume 1,521,179
Day high $0.33 Avg. volume 1,859,336
50-day MA $0.53 Dividend yield N/A
200-day MA $1.29 Market Cap 21.78M

Kala Pharmaceuticals, Inc. (KALA) Company Bio

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles technology. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is based in Waltham, Massachusetts.

KALA Latest News Stream

Event/Time News Detail
Loading, please wait...

KALA Latest Social Stream

Loading social stream, please wait...

View Full KALA Social Stream

Latest KALA News From Around the Web

Below are the latest news stories about Kala Pharmaceuticals Inc that investors may wish to consider to help them evaluate KALA as an investment opportunity.

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

ARLINGTON, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 15,000 shares of Kala Pharmaceuticals common stock to the new employee. The stock options were granted on February 15, 2022. The

Yahoo | February 18, 2022

Will Kala Pharmaceuticals (KALA) Report Negative Q4 Earnings? What You Should Know

Kala Pharma (KALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

Kala Pharmaceuticals (KALA) Investor Presentation (Slideshow)

No summary available.

Seeking Alpha | January 11, 2022

$3.49 Million in Sales Expected for Kala Pharmaceuticals, Inc. (NASDAQ:KALA) This Quarter

Equities analysts expect Kala Pharmaceuticals, Inc. (NASDAQ:KALA) to post sales of $3.49 million for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for Kala Pharmaceuticals earnings, with estimates ranging from $3.24 million to $4.01 million. Kala Pharmaceuticals posted sales of $2.24 million in the same quarter last year, which []

Dakota Financial News | December 10, 2021

Towercrest Capital Management Buys Aptevo Therapeutics Inc, PowerShares QQQ Trust Ser 1, ...

Newtown, PA, based Investment company Towercrest Capital Management (Current Portfolio) buys Aptevo Therapeutics Inc, PowerShares QQQ Trust Ser 1, Invesco S&P 500 Equal Weight ETF, Impel NeuroPharma Inc, Kala Pharmaceuticals Inc, sells Vanguard FTSE Emerging Markets ETF, International Business Machines Corp during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Towercrest Capital Management.

Yahoo | December 10, 2021

Read More 'KALA' Stories Here

KALA Price Returns

1-mo -13.84%
3-mo -77.10%
6-mo -75.21%
1-year -94.34%
3-year -95.31%
5-year N/A
YTD -75.21%
2021 -82.15%
2020 83.74%
2019 -24.54%
2018 -73.55%
2017 N/A

Continue Researching KALA

Want to see what other sources are saying about Kala Pharmaceuticals Inc's financials and stock price? Try the links below:

Kala Pharmaceuticals Inc (KALA) Stock Price | Nasdaq
Kala Pharmaceuticals Inc (KALA) Stock Quote, History and News - Yahoo Finance
Kala Pharmaceuticals Inc (KALA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.5367 seconds.